BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND STAT3, FLJ20882, 6774, ENSG00000168610, APRF, P40763, MGC16063 AND Diagnosis
13 results:

  • 1. Molecular Landscape of LncRNAs in prostate cancer: A focus on pathways and therapeutic targets for intervention.
    Mirzaei S; Paskeh MDA; Okina E; Gholami MH; Hushmandi K; Hashemi M; Kalu A; Zarrabi A; Nabavi N; Rabiee N; Sharifi E; Karimi-Maleh H; Ashrafizadeh M; Kumar AP; Wang Y
    J Exp Clin Cancer Res; 2022 Jul; 41(1):214. PubMed ID: 35773731
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Dual STAT‑3 and IL‑6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL‑6/IL‑6R/STAT‑3 axis.
    Méndez-Clemente A; Bravo-Cuellar A; González-Ochoa S; Santiago-Mercado M; Palafox-Mariscal L; Jave-Suárez L; Solorzano-Ibarra F; Villaseñor-García M; Ortiz-Lazareno P; Hernández-Flores G
    Oncol Rep; 2022 Aug; 48(2):. PubMed ID: 35703345
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Identification of Potential Key Genes in prostate cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.
    Khan MM; Mohsen MT; Malik MZ; Bagabir SA; Alkhanani MF; Haque S; Serajuddin M; Bharadwaj M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456461
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. stat3-regulated LncRNA LINC00160 mediates cell proliferation and cell metabolism of prostate cancer cells by repressing RCAN1 expression.
    Zhu W; Sheng D; Shao Y; Zhang Q; Peng Y
    Mol Cell Biochem; 2022 Mar; 477(3):865-875. PubMed ID: 35067783
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. PIWI‑interacting RNA in cancer: Molecular mechanisms and possible clinical implications (Review).
    Yuan C; Qin H; Ponnusamy M; Chen Y; Lin Z
    Oncol Rep; 2021 Sep; 46(3):. PubMed ID: 34328192
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Examining the relationship between diabetes and prostate cancer through changes in screening guidelines.
    Miller EA; Pinsky PF
    Cancer Causes Control; 2020 Dec; 31(12):1105-1113. PubMed ID: 32970300
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision-making processes.
    Long X; Wu L; Zeng X; Wu Z; Hu X; Jiang H; Lv Z; Yang C; Cai Y; Yang K; Li Y
    Cancer Med; 2020 Oct; 9(20):7524-7536. PubMed ID: 32860339
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Tocotrienols: The promising analogues of vitamin E for cancer therapeutics.
    Sailo BL; Banik K; Padmavathi G; Javadi M; Bordoloi D; Kunnumakkara AB
    Pharmacol Res; 2018 Apr; 130():259-272. PubMed ID: 29496592
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MicroRNA-124a inhibits cell proliferation and migration in liver cancer by regulating interleukin-11.
    Yu L; Wang S; Lin X; Lu Y; Gu P
    Mol Med Rep; 2018 Mar; 17(3):3972-3978. PubMed ID: 29286137
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/stat3 and Aurora kinase A pathways in TRAMP mice.
    Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
    Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Hypoxia preconditioning of mesenchymal stromal cells enhances PC3 cell lymphatic metastasis accompanied by VEGFR-3/CCR7 activation.
    Huang X; Su K; Zhou L; Shen G; Dong Q; Lou Y; Zheng S
    J Cell Biochem; 2013 Dec; 114(12):2834-41. PubMed ID: 23939705
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential.
    Assikis VJ; Do KA; Wen S; Wang X; Cho-Vega JH; Brisbay S; Lopez R; Logothetis CJ; Troncoso P; Papandreou CN; McDonnell TJ
    Clin Cancer Res; 2004 Oct; 10(20):6770-8. PubMed ID: 15501953
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.